Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo. J of Skin [Internet]. 2019 Nov. 9 [cited 2025 Apr. 19];3:S53. Available from: https://skin.dermsquared.com/skin/article/view/781